Background
Pancreatic cancer has an extremely poor prognosis and is indeed the fourth leading cause of cancer-related deaths in the United States. The 5-y survival rate of pancreatic cancer patients is approximately 6%, and the median survival time upon diagnosis is 6 mos. Over the past several decades, these statistics have improved by very little. Pancreatic ductal adenocarcinoma (PDAC) is the most common histological type of pancreatic cancer, accounting for over 95% of cases and mortality. 1 Pancreatic cancer lesions include not only aggressively growing malignant ducts, but also a dense stromal microenvironment, termed "desmoplasia," which fosters tumorigenesis and the inherent resistance of this neoplasm to almost all treatments, including chemotherapy (be it conventional or targeted), radiotherapy and immunotherapy.
The microenvironment of pancreatic cancer comprises neoplastic cells, a non-malignant cellular component as well as conspicuous deposits of extracellular matrix. Pancreatic stellate cells (PSCs, akin to cancer-associated fibroblasts, CAFs) 2 and immune cells 3 are the most prominent non-malignant cells of the pancreatic tumor microenvironment. In normal conditions, PSCs exist in a quiescent state, sparsely disseminated around pancreatic ducts and acini, and operate as stores of vitamin A droplets. Upon inflammation, injury or hitherto unidentified stimuli, PSCs are activated to proliferate in an uncontrolled manner, leading to fibrosis. PSCs have been recognized as a pancreas-specific mesenchymal cell compartment that plays a key role in the fibrotic stroma, forming up to 90% of the tumor volume, a property that is unique to pancreatic cancer. 4 Immune cells that infiltrate the pancreatic microenvironment include components of both the innate and adaptive immune systems, such as macrophages, dendritic cells, lymphocytes and mast cells. 5 Mast cells, multifaceted tissue-homing secretory cells, have been intensively investigated during the past century for their contribution to fibrotic responses in the course of chronic inflammation as well as for their central role in allergic and anaphylactic conditions. Recently, mast cells have attributed a key role in tumor progression, as their intratumoral abundance has been shown to correlate with improved or worsened prognosis in patients affected by a variety of malignancies. 6 Mast cells tend to cluster at the peripheral invasive edges of pancreatic cancers, and three reports indicate that high amounts of these cells correlate with worse prognosis in this setting. [7] [8] [9] However, the exact mechanism whereby mast cells contribute to the progression of pancreatic cancer is complex and far from being defined. Moreover, whether inhibiting the activity of mast cells or preventing their infiltration into neoplastic lesions can affect the outcome of pancreatic cancer remains an open conundrum. We hypothesized that mast cells promote the growth of both PSCs and pancreatic cancer cells, thus contributing to tumor progression as well as to the establishment of a pronounced desmoplastic microenvironment.
Mast Cells are Essential for the Desmoplastic Microenvironment of Pancreatic Cancer
To examine the dynamics of mast cells in pancreatic cancer and understand the mutual relationships between mast cells, malignant cells and PSCs, we established an in vitro co-culture system. 10 Because high amounts of mast cells are found in pancreatic carcinomas, [7] [8] [9] but few of these cells infiltrate the normal pancreas, we first wished to determine whether pancreatic cancer cells or PSCs stimulate the recruitment of mast cells to the tumor microenvironment. We found that pancreatic cancer cells, but not PSCs, induce mast cell migration. Our findings suggest that both malignant cells and PSCs promote the degranulation of tumor-infiltrating mast cells and stimulate them to secrete cytokines. In turn, activated mast cells favor the proliferation of pancreatic cancer cells and PSCs. In particular, we observed that mast cell-derived cytokines including interleukin-13 (IL-13) and tryptase drive the proliferation of stromal cells. The secretion of transforming growth factor β2 (TGFβ2) by PSCs was also upregulated, in turn activating a SMAD2-dependent signal transduction cascade that accelerates the deposition of extracellular matrix components and fibrosis. Thus, malignant pancreatic cells promote the recruitment of mast cells to the tumor microenvironment. In this setting, both malignant cells and PSCs activate mast cells to release cytokines that stimulate their own proliferation. Such an interaction between pancreatic cancer cells, PSCs and mast cell eventually culminates in a feedforward circuitry leading to tumor progression (Fig. 1) . These findings establish a new paradigm in pancreatic cancer, namely, that mast cells promote pancreatic tumorigenesis by exacerbating the cellular and extracellular signaling in the desmoplastic microenvironment.
Prospective on Developing Mast Cell-Targeting Anticancer Therapies
Following the results obtained with our in vitro co-culture system, we hypothesized that inhibiting the migration of mast cells to neoplastic lesions and/or blocking their activation in situ might affect the growth of pancreatic cancer in vivo. To address this hypothesis, we took advantage of an orthotopic PDAC mouse model. Indeed, blocking the migration of mast cells with the chemokine (C-X-C motif) receptor 4 (CXCR4) antagonist AMD3100 or inhibiting mast cell activation with the well-known mast cell stabilizer cromolyn, disrupted the reinforcing interactions between malignant cells, PSCs and mast cells. The significant tumor shrinkage observed in cromolyn-treated tumor-bearing mice and the prolonged survival of AMD3100-treated tumorbearing animals indicate that blocking mast cell function in the tumor microenvironment may be a key intervention to interrupt pancreatic cancer progression. Our findings demonstrate that mast cells contribute to the desmoplastic microenvironment of pancreatic cancer by promoting the proliferation of PSCs, and suggest that targeting mast cells can block disease progression and improve the survival of immunocompetent hosts affected by this neoplasm. 10 Manipulating the migration and activation of mast cells might therefore be translated to the clinic in a neoadjuvant setting, to increase the survival of pancreatic cancer patients.
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